Follow-up care of patients with breast cancer

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 45-50

  Tolaney, Sara M ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Guidelines; Locoregional recurrence; Metastasis; Staging; Surveillance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GABAPENTIN; PAROXETINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VENLAFAXINE; VITAMIN D;

AMENORRHEA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; BREAST SELF EXAMINATION; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOMA IN SITU; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ECHOGRAPHY; EXERCISE; FALSE POSITIVE RESULT; FATIGUE; FOLLOW UP; HEALTH CARE COST; HEART DISEASE; HETEROZYGOTE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; LEUKEMIA; MAMMOGRAPHY; MENOPAUSAL SYNDROME; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVARIECTOMY; OVARY INSUFFICIENCY; PAGET NIPPLE DISEASE; PARTIAL MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; SEXUAL DYSFUNCTION; SIDE EFFECT; THORAX RADIOGRAPHY; UNITED STATES; VAGINA DISCHARGE; VAGINAL DRYNESS; WEIGHT GAIN;

EID: 35648976995     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.005     Document Type: Article

References (56)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Chen E.A., Carlson G.A., Coughlin B.F., et al. Routine chest roentgenography is unnecessary in the work-up of stage I and II breast cancer. J Clin Oncol 18 (2000) 3503-3506
3. Myers R.E., Johnston M., Pritchard K., et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 164 (2001) 1439-1444
4. Curigliano G., Ferretti G., Colleoni M., et al. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. Ann Oncol 12 (2001) 724-725
5. Crump M., Goss P.E., Prince M., et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14 (1996) 66-69
6. Drotman M.B., Machnicki S.C., Schwartz L.H., et al. Breast cancer: assessing the use of routine pelvic CT in patient evaluation. Am J Roentgenol 176 (2001) 1433-1436
7. Meyer J.I., Herts B.R., Einstein D.M., et al. Pelvic computed tomography of breast carcinoma patients. Should it routinely be added to abdominal computed tomography?. Cancer 79 (1997) 500-504
8. Carr CE, Rosen MA, Schnall MD, Davidson R. The impact of FDG PET in the staging of breast cancer. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 2006;24:530.
9. Dawson L.A., Chow E., and Goss P.E. Evolving perspectives in contralateral breast cancer. Eur J Cancer 34 (1998) 2000-2009
10. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22 (2004) 2328-2335
11. Bernstein J.L., Thompson W.D., Risch N., et al. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136 (1992) 925-936
12. Arpino G., Bardou V.J., Clark G.M., et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6 (2004) R149-R156
13. Grunfeld E., Noorani H., McGahan L., et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 11 (2002) 228-235
14. Boyd N.F., Guo H., Martin L.J., et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (2007) 227-236
15. Lehman C.D., Gatsonis C., Kuhl C.K., et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356 (2007) 1295-1303
16. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 (2007) 75-89
17. Thomas D.B., Gao D.L., Ray R.M., et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (2002) 1445-1457
18. Fisher B., Anderson S., Fisher E.R., et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338 (1991) 327-331
19. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
20. de Bock G.H., Bonnema J., van der Hage J., et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol 22 (2004) 4010-4018
21. Buchanan C.L., Dorn P.L., Fey J., et al. Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 203 (2006) 469-474
22. Neville A.M., Bettelheim R., Gelber R.D., et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (1992) 696-705
23. Faneyte I.F., Peterse J.L., Van Tinteren H., et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 10 (2004) 4457-4463
24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
25. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
26. Lin N.U., and Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 13 (2007) 1648-1655
27. James J.J., Evans A.J., Pinder S.E., et al. Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. Br J Cancer 89 (2003) 660-665
28. Clavien P.A., Laffer U., Torhost J., et al. Gastro-intestinal metastases as first clinical manifestation of the dissemination of a breast cancer. Eur J Surg Oncol 16 (1990) 121-126
29. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271 (1994) 1587-1592
30. Rosselli Del Turco M., Palli D., Cariddi A., et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 271 (1994) 1593-1597
31. Palli D., Russo A., Saieva C., et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA 281 (1999) 1586
32. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev: CD001768; 2005.
33. Warner E. Intensive radiologic surveillance: a focus on the psychological issues. Ann Oncol 15 Suppl. 1 (2004) I43-I47
34. Barton M.B., Morley D.S., Moore S., et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst 96 (2004) 529-538
35. Makari-Judson G., Judson C.H., and Mertens W.C. Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. Breast J 13 (2007) 258-265
36. Levine E.G., Raczynski J.M., and Carpenter J.T. Weight gain with breast cancer adjuvant treatment. Cancer 67 (1991) 1954-1959
37. Walshe J.M., Denduluri N., and Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24 (2006) 5769-5779
38. Postma T.J., Vermorken J.B., Liefting A.J., et al. Paclitaxel-induced neuropathy. Ann Oncol 6 (1995) 489-494
39. Hurria A., and Lachs M. Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer?. Breast Cancer Res Treat (2007)
40. Vardy J., Rourke S., and Tannock I.F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007)
41. Ganz P.A., and Bower J.E. Cancer related fatigue: a focus on breast cancer and Hodgkin's disease survivors. Acta Oncol 46 (2007) 474-479
42. Broeckel J.A., Thors C.L., Jacobsen P.B., et al. Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat 75 (2002) 241-248
43. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19 (2001) 37-43
44. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
45. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
46. Chaplain G., Milan C., Sgro C., et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 18 (2000) 2836-2842
47. Bordeleau L., Pritchard K., Goodwin P., et al. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 29 (2007) 230-241
48. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
49. Berruti A., Tucci M., Mosca A., et al. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients. J Clin Oncol 25 (2007) 1455-1456
50. Burstein H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast (2007)
51. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
52. Grunfeld E., Mant D., Yudkin P., et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 313 (1996) 665-669
53. Grunfeld E., Fitzpatrick R., Mant D., et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract 49 (1999) 705-710
54. Grunfeld E., Gray A., Mant D., et al. Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer 79 (1999) 1227-1233
55. Grunfeld E., Levine M.N., Julian J.A., et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 24 (2006) 848-855
56. Khatcheressian J.L., Wolff A.C., Smith T.J., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24 (2006) 5091-5097